Infliximab-associated immunomediated hepatitis in children with inflammatory bowel disease

Shikib Mostamand, Shauna Schroeder, Jacqueline Schenkein, Tamir Miloh

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Infliximab (IFX) is commonly used to induce and maintain remission in inflammatory bowel disease (IBD). We report the first 2 cases of children with ulcerative colitis who had normal liver transaminases before IFX and were diagnosed with immunomediated hepatitis after IFX induction. Both the cases had negative antibodies for antinuclear, smooth muscle, and liver kidney microsome, with 1 patient having positive autoimmune serology (dsDNA) and overlap primary sclerosing cholangitis. IFX was discontinued and transaminases normalized without steroid administration. Clinicians treating pediatric patients with IBD with IFX should be aware of IFX immunomediated hepatitis. This phenomenon is previously reported in adult patients with IBD. To our knowledge, these are the first cases reported in pediatric patients with IBD.

Original languageEnglish (US)
Pages (from-to)94-97
Number of pages4
JournalJournal of pediatric gastroenterology and nutrition
Issue number1
StatePublished - Jul 1 2016
Externally publishedYes


  • autoimmune hepatitis
  • Crohn disease
  • hepatitis
  • immunomediated hepatitis
  • inflammatory bowel disease
  • infliximab
  • primary sclerosing cholangitis
  • transaminases
  • ulcerative colitis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology


Dive into the research topics of 'Infliximab-associated immunomediated hepatitis in children with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this